Catalyst Pharmaceuticals (CPRX) News Today $21.15 -0.24 (-1.12%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Stephens & Co. Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Overweight RecommendationNovember 19 at 11:13 PM | msn.comCatalyst Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 19 at 8:03 AM | globenewswire.comCatalyst Pharmaceuticals initiated with an Overweight at StephensNovember 19 at 3:57 AM | markets.businessinsider.comGSA Capital Partners LLP Makes New $625,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)GSA Capital Partners LLP bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 31,437 shares of the biopharmaceutical company's stock, valued at apNovember 19 at 3:48 AM | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at StephensStephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday. They set an "overweight" rating and a $35.00 price target for the company.November 18 at 9:05 AM | marketbeat.comPrincipal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Principal Financial Group Inc. cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 9.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 575,953 shares of the biopharmaceutical company's stoNovember 18 at 3:22 AM | marketbeat.comRoyce & Associates LP Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Royce & Associates LP decreased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,021,105 shares of the biopharmaceutical company's stock after selling 140,917November 15, 2024 | marketbeat.comCatalyst Pharmaceuticals Board Member Trades $11.51M In Company StockNovember 15, 2024 | benzinga.comCatalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting PointNovember 13, 2024 | finance.yahoo.comCatalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to WorkNovember 13, 2024 | globenewswire.comLos Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Los Angeles Capital Management LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 159.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 200,282 shares of the biopharmaceutical companyNovember 13, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) vs. Antibe Therapeutics (OTCMKTS:ATBPF) Financial ComparisonNovember 12, 2024 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by AnalystsCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has received an average rating of "Buy" from the six analysts that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts thNovember 12, 2024 | marketbeat.comCWA Asset Management Group LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)CWA Asset Management Group LLC acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 26,845 shares of the biopharmaceutical company's stock, valued atNovember 12, 2024 | marketbeat.comCatalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 11, 2024 | finance.yahoo.comCatalyst Pharmaceuticals price target raised to $36 from $30 at TruistNovember 11, 2024 | markets.businessinsider.comTruist Financial Raises Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $36.00Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a report on Monday.November 11, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio ManagementMeritage Portfolio Management grew its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 121.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,914 shareNovember 11, 2024 | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Catalyst Pharma (CPRX)November 9, 2024 | markets.businessinsider.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comCatalyst Pharmaceuticals' (CPRX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday.November 8, 2024 | marketbeat.comWith EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting CaseNovember 8, 2024 | finance.yahoo.comCatalyst Pharmaceuticals Reports Strong Q3 2024 EarningsNovember 8, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Catalyst Pharma (CPRX)November 8, 2024 | markets.businessinsider.comCatalyst Pharmaceuticals reports Q3 non-GAAP EPS 57c, consensus 30cNovember 7, 2024 | markets.businessinsider.comCatalyst Pharmaceuticals sees FY24 revenue $475M-$485M, consensus $473.67MNovember 7, 2024 | markets.businessinsider.comCatalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Report Preview: What To Look ForNovember 6, 2024 | finance.yahoo.comCatalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year High - What's Next?Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 12-Month High - Should You Buy?November 1, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Grows Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)DekaBank Deutsche Girozentrale boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 48.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 183,376 shares of the biopharmaceuticalNovember 1, 2024 | marketbeat.comCatalyst Pharmaceuticals (CPRX) Scheduled to Post Earnings on WednesdayCatalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638181)October 30, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 146.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 366,444 shares of the biopharmaceutical compOctober 28, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 1-Year High - What's Next?Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 12-Month High - Time to Buy?October 25, 2024 | marketbeat.comCatalyst Pharmaceuticals Inc. stock rises Thursday, still underperforms marketOctober 25, 2024 | marketwatch.comCatalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024October 22, 2024 | globenewswire.com50,500 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Purchased by Toth Financial Advisory CorpToth Financial Advisory Corp acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 50,500 shares of the biopharmaceutical companyOctober 21, 2024 | marketbeat.comCatalyst Pharmaceuticals IncOctober 19, 2024 | money.usnews.comFriedenthal Financial Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Friedenthal Financial acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 37,139 shares of the biopharmaceutical company's stoOctober 19, 2024 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from AnalystsCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has received an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target amonOctober 18, 2024 | marketbeat.comBfsg LLC Invests $3 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Bfsg LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 150,927 shares of the biopharmaceutical company's stockOctober 17, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 12-Month High - Here's What HappenedCatalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year High - What's Next?October 16, 2024 | marketbeat.comCubist Systematic Strategies LLC Sells 233,967 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Cubist Systematic Strategies LLC trimmed its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 96.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,523 shares of the biopharmaceuticalOctober 16, 2024 | marketbeat.comOliver Luxxe Assets LLC Purchases Shares of 34,025 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Oliver Luxxe Assets LLC acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 34,025 shares of the biopharmaceutical company's stock, valueOctober 15, 2024 | marketbeat.comLivforsakringsbolaget Skandia Omsesidigt Boosts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 48.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 110,900 shares of thOctober 13, 2024 | marketbeat.comSquarepoint Ops LLC Reduces Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Squarepoint Ops LLC reduced its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 90.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 18,272 shares of the biopharmaceutical company's stock after selling 170,088 shares durinOctober 12, 2024 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comWith 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional ownersOctober 10, 2024 | finance.yahoo.comCatalyst Pharmaceuticals Inc (CPRX) Q2 2024 Earnings Call Highlights: Revenue Surge and ...October 10, 2024 | finance.yahoo.comCatalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief EffortsOctober 8, 2024 | globenewswire.comQ3 2025 EPS Estimates for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Lifted by Zacks ResearchCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Stock analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research report issued to clients and investors on Thursday, October 3rd. Zacks Research analyst A. Chakraborty nOctober 7, 2024 | marketbeat.com Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide CPRX Media Mentions By Week CPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼0.600.46▲Average Medical News Sentiment CPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼95▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDYA News ANIP News CUE News DRRX News SRPT News RVMD News QGEN News ITCI News ROIV News ASND News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
